AstraZeneca plc

09/13/2024 | Press release | Distributed by Public on 09/13/2024 08:16

Director/PDMR Shareholding

English
Published: 2024-09-13 16:15:00 CEST

AstraZeneca PLC
Major shareholder announcements

Director/PDMR Shareholding

13 September 2024 15:15 BST

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that Michel Demaré, Non-Executive Chair of the Board, purchased 2,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 13 September 2024.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Michel Demaré
2 Reason for the notification
a) Position/status Non-Executive Chair of the Board
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of US$0.25 each in AstraZeneca PLC

GB0009895292

b) Nature of the transaction Purchase of AstraZeneca PLC Ordinary Shares of US$0.25
c) Price(s) and volume(s)
Price(s) Volume(s)
£117.927465 2,000
d) Aggregated information

- Aggregated volume

- Price
Not applicable - single transaction
e) Date of the transaction 13 September 2024
f) Place of the transaction LON
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.comand follow the Company on social media @AstraZeneca

Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected]or visit www.rns.com.


Attachments:
09138225.pdf

This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page